BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has received a consensus rating of “Buy” from the nine research firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $4.57.
Several research firms recently commented on BDSI. Zacks Investment Research upgraded shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a report on Wednesday, February 14th. Seaport Global Securities began coverage on shares of BioDelivery Sciences International in a report on Friday, January 26th. They set a “buy” rating and a $5.00 price target for the company. HC Wainwright set a $5.00 price target on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a report on Monday, November 27th. Finally, Roth Capital set a $5.00 price target on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a report on Monday, November 13th.
In related news, Director Mark A. Sirgo sold 709,502 shares of the business’s stock in a transaction on Friday, January 19th. The shares were sold at an average price of $2.73, for a total transaction of $1,936,940.46. Following the transaction, the director now owns 1,759,262 shares of the company’s stock, valued at $4,802,785.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark A. Sirgo sold 162,509 shares of the business’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $2.78, for a total transaction of $451,775.02. Following the transaction, the director now directly owns 1,759,262 shares in the company, valued at approximately $4,890,748.36. The disclosure for this sale can be found here. In the last three months, insiders sold 980,011 shares of company stock worth $2,666,275. Insiders own 7.73% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN increased its position in BioDelivery Sciences International by 138.2% during the third quarter. Wells Fargo & Company MN now owns 35,506 shares of the specialty pharmaceutical company’s stock worth $105,000 after acquiring an additional 20,599 shares during the period. JPMorgan Chase & Co. bought a new position in BioDelivery Sciences International during the third quarter worth $116,000. Advisor Group Inc. increased its position in BioDelivery Sciences International by 42.1% during the second quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock worth $126,000 after acquiring an additional 13,341 shares during the period. Two Sigma Investments LP bought a new position in BioDelivery Sciences International during the fourth quarter worth $166,000. Finally, BlueCrest Capital Management Ltd bought a new position in BioDelivery Sciences International during the fourth quarter worth $201,000. 43.98% of the stock is currently owned by institutional investors and hedge funds.
BioDelivery Sciences International (NASDAQ BDSI) remained flat at $$2.10 during mid-day trading on Friday. The company had a trading volume of 492,000 shares, compared to its average volume of 559,821. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.28 and a quick ratio of 1.07. The firm has a market capitalization of $117.36, a price-to-earnings ratio of -11.16 and a beta of 0.50. BioDelivery Sciences International has a one year low of $1.55 and a one year high of $3.60.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.